
Claims


1. Use of a compound of formula I or a pharmacologically acceptable salt thereof



I

in the manufacture of a medicament for the treatment of a brain cancer selected from an *O*^{6}-alkylguanine DNA alkyltransferase (MGMT) positive astrocytic brain tumour, a metastatic brain cancer and primary central nervous system (CNS) lymphoma.

2. Use of a compound of formula I or a pharmacologically acceptable salt thereof



I

in the manufacture of a medicament for the treatment of *O*^{6}-alkylguanine DNA alkyltransferase (MGMT) positive glioblastoma multiforme.

3. Use according to claim 1, wherein the MGMT positive astrocytic brain tumour is selected from a diffuse (WHO grade II) astrocytoma and an anaplastic (WHO grade III) astrocytoma.
4. Use according to claim 1, wherein the metastatic brain cancer is selected from metastasized breast cancer, metastasized systemic lymphoma, metastasized lung cancer, metastasized melanoma, metastasized sarcoma and metastasized gastro-intestinal cancer.

5. Use according to claim 1, wherein the metastatic brain cancer is metastasized breast cancer.

6. Use according to any one of claims 1 to 5, wherein the pharmacologically acceptable salt of the compound of formula I is the hydrochloride,

hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate or acetate.

7. Use according to any one of claims 1 to 6, wherein the medicament is adapted for intravenous administration to a patient in need thereof at a dosage level of from 0.1 mg/kg to 70 mg/kg body weight patient.

8. Use according to claim 7, wherein the medicament is adapted for intravenous administration to the patient in need thereof at a dosage level of from 0.5 mg/kg to 50 mg/kg body weight patient.

9. Use according to claim 7 or claim 8, wherein the medicament is adapted for intravenous administration to the patient in need thereof on days 1, 8 and 15 of a treatment cycle, on days 1 and 8 of a treatment cycle or day 1 only of a treatment cycle.

10. Use according to any one of claims 1 to 9, wherein the medicament is to be administered in conjunction with radiotherapy, where the radiotherapy is to be given either prior to or after administration of said medicament.

11. Use according to claim 10, wherein the radiotherapy is to be given prior to administration of said medicament.

12. Use according to any one of claims 1 to 9, wherein the medicament is to be administered in conjunction with radiotherapy.

13. Use according to any one of claims 10 to 12, wherein the radiotherapy is to be given at a dose of 1 to 5 Gy over 5 consecutive days, and preferably 2 Gy over 5 consecutive days.

14. Use according to any one of claims 1 to 13, wherein the medicament is to be administered concurrently, sequentially or separately with a vascular endothelial growth factor (VEGF) inhibitor.

15. Use according to claim 14, wherein said vascular endothelial growth factor (VEGF) inhibitor is bevacizumab.

16. Use according to any one of claims 1 to 13, wherein the medicament is to be administered concurrently, sequentially or separately with a poly ADP ribose polymerase (PARP) inhibitor.

17. Use according to claim 16, wherein said poly ADP ribose polymerase (PARP) inhibitor is selected from rucaparib, olaparib and veliparib.

18. Use according to any one of claims 1 to 13, wherein the medicament is to be administered concurrently, sequentially or separately with a PD-1/PDL-1 (immune checkpoint) inhibitor.

19. Use according to claim 18, wherein said PD-1/PDL-1 (immune checkpoint) inhibitor is ipilimumab.